NSE AUROPHARMA · BSE 524804 · Major Drugs · NIFTY 500

Aurobindo Pharma Share Price

Market closed · updated 25 Sep, 4:30 PM IST

₹1,724.70 ▲ +₹0.00 · 0.00% NSE · as of 24 Sep 2026, 8:46 AM · BSE ₹1,725.00

Today's range

₹1,711.25Low₹1,739.60High

52-week range

₹1,066.00Low · 8 Oct 2025₹1,739.00High · 21 Sep 2026

Aurobindo Pharma Overview

Where the price stands, how it has moved and how it sits against its averages.

Aurobindo Pharma shares last traded at ₹1,724.70 on the NSE, up 0.00% on the day. That is 0.8% below the 52-week high of ₹1,739.00 and 61.8% above the 52-week low of ₹1,066.00. The stock trades at 24.67× earnings, below the sector average of 36.50. Its market value is ₹99,253 Cr.

Price returns

1 Day0.00%

5 Days▲ +4.78%

This month▲ +0.26%

3 Months▲ +12.47%

6 Months▲ +31.63%

This year▲ +45.52%

1 Year▲ +55.10%

Against the market: 1 Month ▲ +9.82% · 3 Months ▲ +15.72% · 6 Months ▲ +32.42% · This year ▲ +65.73% · 1 Year ▲ +70.18%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 6 of 6

Today's price₹1,724.70
5-day average₹1,696.08 ▲ price 1.7% above
10-day average₹1,687.95 ▲ price 2.2% above
20-day average₹1,667.48 ▲ price 3.4% above
50-day average₹1,620.86 ▲ price 6.4% above
100-day average₹1,554.46 ▲ price 11.0% above
300-day average₹1,395.06 ▲ price 23.6% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Aurobindo Pharma Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore

33,653

Net profit₹ crore · losses below zero

5,335

3,505

Year by year

Fiscal year	Revenue	Growth	Net profit	Net margin	EPS	Dividend
FY 2026	₹33,653 Cr	▲ +6.1%	₹3,505 Cr	10.4%	₹60.34	—
FY 2025	₹31,724 Cr	▲ +9.4%	₹3,486 Cr	11.0%	₹59.81	₹0.00
FY 2024	₹29,002 Cr	▲ +16.7%	₹3,173 Cr	10.9%	₹54.15	₹4.50
FY 2023	₹24,855 Cr	▲ +6.0%	₹1,928 Cr	7.8%	₹32.90	₹3.00
FY 2022	₹23,455 Cr	▼ −5.3%	₹2,648 Cr	11.3%	₹45.20	₹9.00
FY 2021	₹24,775 Cr	▲ +7.3%	₹5,335 Cr	21.5%	₹91.05	₹4.00
FY 2020	₹23,099 Cr	—	₹2,845 Cr	12.3%	₹48.56	₹3.00

Revenue₹ crore

9,150

Net profit₹ crore · losses below zero

1,033

Quarter by quarter

Quarter	Revenue	vs prev. qtr	Net profit	Net margin	EPS
Q1 FY27	₹9,150 Cr	▲ +3.4%	₹1,033 Cr	11.3%	₹17.86
Q4 FY26	₹8,853 Cr	▲ +2.4%	₹921 Cr	10.4%	₹15.86
Q3 FY26	₹8,646 Cr	▲ +4.3%	₹910 Cr	10.5%	₹15.67
Q2 FY26	₹8,286 Cr	▲ +5.3%	₹848 Cr	10.2%	₹14.61
Q1 FY26	₹7,868 Cr	▼ −6.1%	₹825 Cr	10.5%	₹14.20
Q4 FY25	₹8,382 Cr	▲ +5.1%	₹903 Cr	10.8%	₹15.56
Q3 FY25	₹7,979 Cr	▲ +2.3%	₹846 Cr	10.6%	₹14.56
Q2 FY25	₹7,796 Cr	—	₹817 Cr	10.5%	₹14.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity

35%

65%

Total assets₹58,502 Cr
Total liabilities₹20,611 Cr
Shareholders' equity₹37,891 Cr
Total debt₹8,073 Cr
Cash & investments₹10,585 Cr
Current ratio1.81×
Revenue growth, 5 yr6.32% a year
EPS growth, 5 yr−7.90% a year
Operating margin (TTM)14.77%
Net margin (TTM)10.62%

Cash flow — FY26

Operating activities

▲ ₹5,527 Cr

Investing activities

▼ −₹3,459 Cr

Financing activities

▼ −₹1,269 Cr

Free cash flow

▲ ₹2,422 Cr

Net change in cash

▲ ₹1,628 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total revenue	23,098.51	24,774.62	23,455.49	24,855.38	29,001.87	31,723.73	33,653.08
Cost of revenue	10,611.91	10,805.28	11,053.50	12,325.90	13,660.15	14,316.16	14,926.79
Gross profit	12,486.60	13,969.34	12,401.99	12,529.48	15,341.72	17,407.57	18,726.29
Operating expenses	19,190.00	17,540.91	20,399.22	22,341.74	24,871.40	26,767.65	28,616.35
Operating income	3,908.51	7,233.71	3,056.27	2,513.64	4,130.47	4,956.08	5,036.73
Depreciation	966.71	1,055.39	1,126.52	1,244.58	1,491.91	1,633.97	1,760.65
Profit before tax	3,743.04	7,343.59	3,372.74	2,612.50	4,379.99	5,066.29	5,111.85
Tax	899.35	2,009.77	725.63	684.85	1,211.02	1,582.72	1,608.88
Net profit	2,845.14	5,334.84	2,648.15	1,927.50	3,172.97	3,485.89	3,504.75
EPS (₹)	48.56	91.05	45.20	32.90	54.15	59.81	60.34
Dividend per share (₹)	3.00	4.00	9.00	3.00	4.50	0.00	—

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total assets	28,927.74	33,853.99	33,921.72	39,889.99	45,071.51	49,784.97	58,502.15
Current assets	16,412.51	19,823.51	18,122.69	21,545.67	24,205.63	27,162.46	32,708.75
Cash & short-term investments	2,834.12	5,621.20	4,557.64	6,232.71	6,326.36	8,201.28	10,584.92
Inventory	7,699.87	9,026.57	7,553.85	8,511.23	9,808.23	10,543.72	12,052.94
Property, plant & equipment	8,116.61	9,315.51	10,666.00	12,491.78	14,284.90	15,455.43	17,338.76
Total liabilities	12,103.07	11,924.12	9,345.74	13,050.14	15,228.71	17,131.65	20,611.18
Current liabilities	11,384.64	10,665.15	8,155.98	11,493.78	12,199.13	14,682.34	18,039.01
Total debt	5,937.35	5,392.02	3,011.16	5,286.21	6,647.63	8,262.87	8,072.84
Total equity	16,824.67	21,929.87	24,575.98	26,839.85	29,842.80	32,653.32	37,890.97

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
From operations	4,381.28	3,351.33	5,013.23	2,393.16	2,434.52	3,925.28	5,526.55
From investing	−1,567.64	598.69	−3,211.56	−3,977.75	−4,255.95	−1,875.80	−3,458.61
From financing	−1,947.18	−1,364.81	−2,969.27	1,814.41	800.42	119.78	−1,269.15
Capital expenditure	−1,431.09	−1,873.81	−2,704.64	−2,720.40	−3,561.50	−2,519.55	−3,104.67
Dividends paid	−175.61	−234.31	−263.70	−439.53	−263.64	−1.04	−232.40
Net change in cash	871.24	2,583.09	−1,167.40	229.76	−1,006.84	2,178.36	1,627.61

What Analysts Say

27 analysts

Recommendations from 27 analysts who cover Aurobindo Pharma.

Buy average rating 2.30 on a 1–5 scale

Strong buyBuyHoldSellStrong sell

▲ 17 bullish (63.0%) · 5 hold (18.5%) · ▼ 5 bearish (18.5%)

Votes

Strong Buy

8 (30%)

Buy

9 (33%)

Hold

5 (19%)

Sell

4 (15%)

Strong Sell

1 (4%)

How the votes changed

Rating	3M ago	2M ago	1M ago	1W ago	Now	3-month change
Strong Buy	8	8	8	8	8	—
Buy	10	10	9	9	9	▼ −1
Hold	5	5	5	5	5	—
Sell	3	3	4	4	4	▲ +1
Strong Sell	1	1	1	1	1	—

Analyst ratings are opinions, not a guarantee of returns.

Aurobindo Pharma vs Peers

Side by side with other major drugs companies. The small bars compare each column.

Company	Price	Change	Market cap	P/E	P/B	ROE (5 yr)	Net margin	Div. yield	Rating
Aurobindo Pharma	₹1,724.70	0.00%	₹99,253 Cr	24.67	2.64	10.25%	10.62%	0.00%	This stock
Neuland Laboratories	₹21,944.85	▼ −2.44%	₹28,047 Cr	64.28	12.62	19.28%	17.99%	0.18%	Neutral
Pfizer	₹4,033.15	▲ +0.40%	₹18,446 Cr	27.53	4.97	19.08%	28.67%	1.64%	Bearish
Unichem Laboratories	₹559.15	▼ −2.41%	₹3,903 Cr	54.27	1.53	1.01%	11.48%	—	Bullish
Jagsonpal Pharmaceuticals	₹242.50	▲ +7.35%	₹1,596 Cr	34.27	5.43	18.10%	15.00%	1.12%	Bullish
Themis Medicare	₹118.30	▼ −3.03%	₹1,086 Cr	632.19	2.54	11.91%	0.33%	0.45%	Neutral

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Aurobindo Pharma shares, quarter by quarter (latest on top).

PromoterFIIMFOther

Jun '26

51.9%

16.4%

16.7%

15.0%

Mar '26

Dec '25

Sep '25

Holder	Sep '25	Dec '25	Mar '26	Jun '26	Change
Promoter	51.82%	51.82%	51.82%	51.88%	▲ +0.06 pts
FII	14.21%	13.95%	15.24%	16.38%	▲ +1.14 pts
MF	19.30%	19.52%	17.79%	16.71%	▼ −1.08 pts
Other	14.67%	14.71%	15.15%	15.03%	▼ −0.12 pts

Aurobindo Pharma Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Aurobindo PharmaBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share

24.67

▼ 32% below the sector average of 36.50

P/E, 12-month rangeLow 8.14 · high 24.67

100%

Today's P/E sits 100% of the way from its low to its high

P/BPrice ÷ book value per share

2.64

P/SPrice ÷ sales per share

2.84

P/CFPrice ÷ cash flow per share

17.78

PEGP/E ÷ earnings growth (≈1 is fair)

1.20

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods

60.28%

▲ above its 5-yr average of 53.55%

Operating marginKept after running costs

14.77%

▲ above its 5-yr average of 13.80%

Pre-tax marginKept before tax

15.51%

▲ above its 5-yr average of 14.40%

Net marginKept as profit

10.62%

▲ above its 5-yr average of 10.32%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money

9.94%

▼ below its 5-yr average of 10.25%

Return on assetsProfit on everything it owns

6.47%

▼ below its 5-yr average of 6.86%

Return on investmentProfit on long-term capital

9.27%

▼ below its 5-yr average of 9.57%

Growth Is the business getting bigger?

Revenue — last 12 months

+9.1%

▲ growing

Revenue — 3 yr, a year

+10.6%

▲ growing

Revenue — 5 yr, a year

+6.3%

▲ growing

EPS — last 12 months

+9.8%

▲ growing

EPS — 3 yr, a year

+22.4%

▲ growing

EPS — 5 yr, a year

−7.9%

▼ shrinking

Book value — 5 yr, a year

+11.8%

▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money

0.21×

✓ Low debt

Current ratioShort-term assets for every ₹1 due within a year

1.81×

✓ Comfortable

Quick ratioLike the current ratio, without inventory

1.15×

✓ Comfortable

Interest coverOperating profit ÷ interest to pay

183.39×

✓ Strong

Payout ratioShare of profit paid as dividend

0.00%

• Keeps most

Per share What each share stands for

EPS (TTM)

₹64.00

Book value

₹652.39

Cash flow

₹96.01

Dividend

₹0.00

Revenue

₹602.19

The share price is 2.64× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 107 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year28.53

Current Dividend Yield - Common Stock Primary Issue, LTM0.00

Price to Book - most recent fiscal year2.64

P/E Basic excluding extraordinary items - TTM24.67

P/E including extraordinary items - TTM26.90

P/E excluding extraordinary items low, trailing 12 months8.14

Price to Tangible Book - most fiscal year3.04

Price to sales - most recent fiscal year2.94

Dividend Yield - indicated annual dividend divided by closing price0.23

Price to Cash Flow per share - trailing 12 month17.78

Peg Ratio1.20

Price to Free Cash Flow per Share - most recent fiscal year45.24

P/E Normalized, most recent fiscal year27.77

P/E excluding extraordinary items high, trailing 12 months24.67

P/E excluding extraordinary items, most recent fiscal year quarter26.90

Price to sales - trailing 12 month2.84

Net Debt, LFY−25,120.80

Per share

Cash Flow per share - trailing 12 month96.01

Cash Flow per share - most recent fiscal year90.63

EPS including extraordinary items - trailing 12 month64.00

EPS including extraordinary items - most recent fiscal year60.34

EBITD per share - trailing 12 month122.79

Revenue/share - trailing 12 month602.19

EPS excluding extraordinary items - trailing 12 month64.00

EPS Basic excluding extraordinary items - most recent fiscal year60.34

EPS Basic excluding extraordinary items - trailing 12 month64.00

Book value per share - most recent fiscal year652.39

Revenue/share - most recent fiscal year579.42

EPS Normalized - most recent fiscal year61.98

Book value (tangible) per share - most recent fiscal year561.46

Dividends per share - trailing 12 month0.00

EPS excluding extraordinary items - most recent fiscal year60.34

Cash per share - most recent fiscal year182.25

Margins

Operating margin - trailing 12 month14.77

Gross Margin - 5 year average53.55

Operating margin - 1st historical fiscal year14.97

Operating Margin - 5 year average13.80

Net Profit Margin % - 1st historical fiscal year10.41

Gross Margin - 1st historical fiscal year55.65

Net Profit Margin % - trailing 12 month10.62

Net Profit Margin - 5 year average10.32

Pretax Margin - 5 year average14.40

Pretax margin - 1st historical fiscal year15.19

Pretax margin - trailing 12 month15.51

Free Operating Cash Flow/Revenue, 5 Year Average2.44

Gross Margin - trailing 12 month60.28

Growth

EPS Change %, TTM over TTM9.75

Revenue growth rate, 5 year6.32

EPS growth rate, 5 year−7.90

Revenue Change % - most recent quarter 1 year ago16.30

Growth rate% - EPS, 3 year22.41

Revenue/share (5 yr growth)6.50

Free Operating Cash Flow, 5 Year CAGR11.98

Tangible Book Value, Total Equity, 5 Year CAGR11.63

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR6.15

Capital Spending growth rate, 5 year10.63

Revenue Change %, TTM over TTM9.09

Growth rate% - Revenue, 3 year10.63

Book value per share growth rate, 5 year11.75

EPS Change % - most recent quarter 1 year ago25.77

Net Profit Margin growth rate, 5 year−13.53

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR4.77

Total Debt, 5 Year CAGR8.41

Financial strength

Net Interest coverage - most recent fiscal year183.39

Free Cash Flow - most recent fiscal year21,894.80

LT debt/equity - most recent fiscal year0.03

Quick ratio - most recent fiscal year1.15

Payout ratio - trailing 12 month0.00

Current ratio - most recent fiscal year1.81

Current EV/Free Cash Flow, LFY50.11

Total debt/total equity - most recent fiscal year0.21

Net Interest coverage - trailing 12 month17.62

Returns & efficiency

Return on average equity - 5 year average10.25

Net Income/employee - trailing 12 month12,70,430.00

Revenue/employee - most recent fiscal year1,18,25,530.00

Return on investment - most recent fiscal year9.27

Return on average assets - most recent fiscal year6.47

Receivables turnover - most recent fiscal year5.18

Inventory turnover - most recent fiscal year1.32

Revenue/employee - trailing 12 month1,19,60,450.00

Return on average assets - 5 year average6.86

Net Income/employee - most recent fiscal year12,30,926.00

Asset turnover - most recent fiscal year0.62

Return on average equity - most recent fiscal year9.94

Return on investment - 5 year average9.57

Price & volume

Market Cap99,177.89

52 week Low Date8 Oct 2025

Price - 1 Day % Change1.26

Relative (S&P500) price percent change - 13 week15.72

Avg trading volume last 10 days0.75

Price - 13 week price percent change12.47

Price - 52 week price percent change55.10

Avg Trading Volume Last 3 months21.30

Price - 5 Day % Change4.78

Price % Change Month To Date0.26

Relative (S&P500) price percent change - 04 week9.82

52 week High Date21 Sep 2026

Price - 26 week price percent change31.63

PDATE23 Sep 2026

Price - YTD price percent change45.52

Relative (S&P500) price percent change - 52 week70.18

NPRICE1,721.50

Relative (S&P500) price percent change - 26 week32.42

52 week Low1,066.80

52 week High1,738.90

Beta0.89

Relative (S&P500) price percent change - Year to Date65.73

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year

₹9.00

₹0.00

Dividend yield0.00%
Payout ratio0.00%
Latest dividend₹4.00 per share · 8 Aug 2025

Corporate calendar

27 Aug 2026MeetingAnnual General Meeting
5 Aug 2026BoardQuarterly Results
21 May 2026BoardAudited Results
6 Apr 2026BoardBuy Back of Shares
30 Mar 2026MeetingPostal Ballot
9 Feb 2026BoardQuarterly Results
5 Nov 2025BoardQuarterly Results
10 Sep 2025MeetingAnnual General Meeting

Show 14 older events

8 Aug 2025Dividend₹4.00 per share · 400% · Interim dividend
4 Aug 2025BoardQuarterly Results & Interim Dividend
26 May 2025BoardAudited Results
20 Mar 2025MeetingPostal Ballot
6 Feb 2025BoardQuarterly Results
29 Aug 2024MeetingAnnual General Meeting
28 Mar 2024MeetingPostal Ballot
20 Feb 2024Dividend₹1.50 per share · 150% · Interim dividend
20 Nov 2023Dividend₹3.00 per share · 300% · Interim dividend
17 Feb 2023Dividend₹3.00 per share · 300% · Interim dividend
6 Jun 2022Dividend₹4.50 per share · 450% · Interim dividend
18 Feb 2022Dividend₹1.50 per share · 150% · Interim dividend
17 Nov 2021Dividend₹1.50 per share · 150% · Interim dividend
27 Aug 2021Dividend₹1.50 per share · 150% · Interim dividend

About Aurobindo Pharma

Major Drugs

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.

Key people

Kambam Nithyananda ReddyExecutive Vice Chairman of the Board, Managing Director, Promoter
Santhanam SubramanianChief Financial Officer
Baddigam Adi ReddyCompliance Officer, Company Secretary
Mettu Madan Mohan ReddyWhole-Time Director

Company facts

NSE symbolAUROPHARMA
BSE code524804
ISININE406A01037
IndustryMajor Drugs
IndexNIFTY 500
Market cap₹99,253 Cr
Revenue (FY26)₹33,653 Cr
Net profit (FY26)₹3,505 Cr

In the News

Recent headlines about Aurobindo Pharma — they open on Mint in a new tab.

Top stocks in focus today: Investors must watch NBCC, BHEL, Bharat Forge shares on Wednesday, 16 Sept | Triggers
On September 16, investors will monitor companies such as Tata Communications and Aurobindo Pharma due to various business updates, including new product launches, joint ventures, and settlement agreements.
15 Sep 2026 · 2 min read · Mint ↗
PE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bn
Private equity firms such as Warburg Pincus and CVC Capital Partners have evinced interest in Orbicular Pharma as the specialty pharma firm explores a stake sale in a deal that will likely value the company up to $1.5 billion.
15 Sep 2026 · 3 min read · Mint ↗
RPG Life Sciences bets on China-plus 1, goes on an API buying spree
The Harsh Goenka group is spending to build a drug-ingredients business, betting that the world's push to rely less on China will favour Indian makers.
6 Sep 2026 · 4 min read · Mint ↗
Bajaj Auto to Info Edge - Jay Thakkar suggests 3 stocks to buy or sell for short-term in F&O segment
Indian equity indices are set to open muted on September 2, influenced by high crude oil prices and weak global cues. Nifty 50 ended below 24,100, with technical indicators suggesting cautious trading ahead. Analysts recommend specific stocks for futures trading based on recent market trends.
2 Sep 2026 · 4 min read · Mint ↗
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 1 September 2026
Indian stock indices Sensex and Nifty 50 are expected to open flat to negative on 1 Sept, influenced by weak global cues. Previous session saw Nifty close below 24,100 with lower momentum. Analysts suggest broader trading range with stocks like Sona BLW and Aurobindo Pharma recommended for buying.
1 Sep 2026 · 3 min read · Mint ↗
Stocks to watch on August 31: M&M, Cupid, Aurobindo Pharma, OLA, KP Green Engineering among shares in focus
On August 31, Indian stock market investors will focus on companies like Royal Orchid Hotels and Mahindra & Mahindra after key updates. Despite a positive closing on August 28, indices faced a three-week losing streak, urging caution among investors.
30 Aug 2026 · 2 min read · Mint ↗
Stock market today: Gift Nifty hints a flat-to-negative start; eight day trading stocks to buy on Friday, 28 August
The Indian stock market is set to open flat to negative on 28 August, following global cues. Both the Sensex and the Nifty 50 ended lower earlier. Crude oil prices dipped, with escalating US-Iran tensions affecting market sentiment amid mixed global cues and an uncertain financial outlook.
28 Aug 2026 · 5 min read · Mint ↗
Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA
Aurobindo Pharma said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary in the US from 17th to 21st August 2026, which concluded with four observations.
24 Aug 2026 · 1 min read · Mint ↗

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Aurobindo Pharma (NSE: AUROPHARMA) last traded at ₹1,724.70 on the NSE, up 0.00% (₹0.00) on the day, as of 24 Sep 2026, 8:46 AM. On the BSE it was ₹1,725.00. The day's range was ₹1,711.25 – ₹1,739.60.

Aurobindo Pharma's 52-week high is ₹1,739.00 (21 Sep 2026) and its 52-week low is ₹1,066.00 (8 Oct 2025). At ₹1,724.70 the share is 0.8% below its high and 61.8% above its low.

Aurobindo Pharma's market capitalisation is ₹99,253 Cr (₹99,253 Cr). It is part of the NIFTY 500 index.

Aurobindo Pharma's P/E ratio (trailing 12 months) is 24.67. The sector average is 36.50, so investors pay 32% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹64.00.

Aurobindo Pharma shares are up 55.10% over the last year, up 45.52% so far this year, up 31.63% over 6 months, up 12.47% over 3 months. Over the last year the stock did 70.18% better than the market.

In FY26 (year to Mar 2026), Aurobindo Pharma reported revenue of ₹33,653 Cr (up 6.08% on the year before) and a net profit of ₹3,505 Cr. Earnings per share were ₹60.34.

Yes. Aurobindo Pharma's latest dividend is ₹4.00 per share (400%, interim dividend), with an ex-date of 8 Aug 2025. The dividend yield is 0.00%. It has paid 8 dividends in the records shown on this page.

Of 27 analysts covering Aurobindo Pharma, 17 are bullish (8 strong buy, 9 buy), 5 say hold and 5 are bearish. The consensus is Buy (average rating 2.30 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 51.88%, FII 16.38%, MF 16.71%, Other 15.03%. Promoter holding rose by 0.06 percentage points from Mar 2026.

Aurobindo Pharma's listed peers in Major Drugs include Neuland Laboratories, Pfizer, Unichem Laboratories, Jagsonpal Pharmaceuticals, Themis Medicare. By market capitalisation it ranks #1 of 6 in this group.

Price returns

Moving averages — price is above 6 of 6

Year by year

Quarter by quarter

Balance sheet — FY26

Cash flow — FY26

Votes

How the votes changed

Valuation Is the price reasonable?

Profitability Of every ₹100 of sales, how much is kept?

Returns & efficiency How well does it use its money?

Growth Is the business getting bigger?

Financial strength Can it pay its bills and debts?

Per share What each share stands for

Valuation

Per share

Margins

Growth

Financial strength

Returns & efficiency

Price & volume

Corporate calendar

Key people

Company facts

Frequently Asked Questions

What is Aurobindo Pharma share price today?

What is the 52-week high and low of Aurobindo Pharma shares?

What is the market capitalisation of Aurobindo Pharma?

What is the P/E ratio of Aurobindo Pharma?

How has Aurobindo Pharma stock performed?

What were Aurobindo Pharma's latest annual results?

Does Aurobindo Pharma pay a dividend?

What do analysts recommend for Aurobindo Pharma shares?

What is the shareholding pattern of Aurobindo Pharma?

Who are Aurobindo Pharma's competitors?